These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 18483302)
1. Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. D'Alise AM; Amabile G; Iovino M; Di Giorgio FP; Bartiromo M; Sessa F; Villa F; Musacchio A; Cortese R Mol Cancer Ther; 2008 May; 7(5):1140-9. PubMed ID: 18483302 [TBL] [Abstract][Full Text] [Related]
2. Structural basis of reversine selectivity in inhibiting Mps1 more potently than aurora B kinase. Hiruma Y; Koch A; Dharadhar S; Joosten RP; Perrakis A Proteins; 2016 Dec; 84(12):1761-1766. PubMed ID: 27699881 [TBL] [Abstract][Full Text] [Related]
3. The Aurora B kinase activity is required for the maintenance of the differentiated state of murine myoblasts. Amabile G; D'Alise AM; Iovino M; Jones P; Santaguida S; Musacchio A; Taylor S; Cortese R Cell Death Differ; 2009 Feb; 16(2):321-30. PubMed ID: 18974773 [TBL] [Abstract][Full Text] [Related]
4. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Walsby E; Walsh V; Pepper C; Burnett A; Mills K Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484 [TBL] [Abstract][Full Text] [Related]
5. Preferential killing of p53-deficient cancer cells by reversine. Jemaà M; Galluzzi L; Kepp O; Boilève A; Lissa D; Senovilla L; Harper F; Pierron G; Berardinelli F; Antoccia A; Castedo M; Vitale I; Kroemer G Cell Cycle; 2012 Jun; 11(11):2149-58. PubMed ID: 22592527 [TBL] [Abstract][Full Text] [Related]
6. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor. Farrell P; Shi L; Matuszkiewicz J; Balakrishna D; Hoshino T; Zhang L; Elliott S; Fabrey R; Lee B; Halkowycz P; Sang B; Ishino S; Nomura T; Teratani M; Ohta Y; Grimshaw C; Paraselli B; Satou T; de Jong R Mol Cancer Ther; 2013 Apr; 12(4):460-70. PubMed ID: 23358665 [TBL] [Abstract][Full Text] [Related]
8. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865 [TBL] [Abstract][Full Text] [Related]
9. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992 [TBL] [Abstract][Full Text] [Related]
10. Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia. Carlos JAEG; Lima K; Coelho-Silva JL; de Melo Alves-Paiva R; Moreno NC; Vicari HP; de Souza Santos FP; Hamerschlak N; Costa-Lotufo LV; Traina F; Machado-Neto JA Cell Oncol (Dordr); 2020 Dec; 43(6):1191-1201. PubMed ID: 32857324 [TBL] [Abstract][Full Text] [Related]
11. Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures. Hiruma Y; Koch A; Hazraty N; Tsakou F; Medema RH; Joosten RP; Perrakis A J Biol Chem; 2017 Sep; 292(35):14496-14504. PubMed ID: 28726638 [TBL] [Abstract][Full Text] [Related]
12. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926 [TBL] [Abstract][Full Text] [Related]
13. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Tyler RK; Shpiro N; Marquez R; Eyers PA Cell Cycle; 2007 Nov; 6(22):2846-54. PubMed ID: 18032922 [TBL] [Abstract][Full Text] [Related]
14. 3-Hydroxyflavone inhibits endogenous Aurora B and induces growth inhibition of cancer cell line. Lang Q; Zhang H; Li J; Xie F; Zhang Y; Wan B; Yu L Mol Biol Rep; 2010 Mar; 37(3):1577-83. PubMed ID: 19437133 [TBL] [Abstract][Full Text] [Related]
15. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590 [TBL] [Abstract][Full Text] [Related]
16. Identification of an Aurora kinase inhibitor specific for the Aurora B isoform. Xie H; Lee MH; Zhu F; Reddy K; Peng C; Li Y; Lim DY; Kim DJ; Li X; Kang S; Li H; Ma W; Lubet RA; Ding J; Bode AM; Dong Z Cancer Res; 2013 Jan; 73(2):716-24. PubMed ID: 23117881 [TBL] [Abstract][Full Text] [Related]
17. Reversine induces autophagic cell death through the AMP-activated protein kinase pathway in urothelial carcinoma cells. Fang CY; Chen JS; Chang SK; Shen CH Anticancer Drugs; 2018 Jan; 29(1):29-39. PubMed ID: 28984683 [TBL] [Abstract][Full Text] [Related]
18. The dietary flavonoid luteolin inhibits Aurora B kinase activity and blocks proliferation of cancer cells. Xie F; Lang Q; Zhou M; Zhang H; Zhang Z; Zhang Y; Wan B; Huang Q; Yu L Eur J Pharm Sci; 2012 Aug; 46(5):388-96. PubMed ID: 22449725 [TBL] [Abstract][Full Text] [Related]
19. Reversine Induced Multinucleated Cells, Cell Apoptosis and Autophagy in Human Non-Small Cell Lung Cancer Cells. Lu YC; Lee YR; Liao JD; Lin CY; Chen YY; Chen PT; Tseng YS PLoS One; 2016; 11(7):e0158587. PubMed ID: 27385117 [TBL] [Abstract][Full Text] [Related]
20. A new small-molecule Aurora B inhibitor shows antitumor activity in human cancer cell lines. Wu Y; Li J; Jiang C; Yang X; Cao L; Yu L Mol Biol Rep; 2015 Feb; 42(2):517-24. PubMed ID: 25348602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]